



Original article

COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)

Marcia Garnica ^{a,b,*}, Edvan De Queiroz Crusoe ^c, Glaciano Ribeiro ^d,
Rosane Bittencourt ^e, Roberto José Pessoa Magalhães ^a,
Karla Richter Zanella ^f, Abrahão Elias Hallack Neto ^g,
Juliana Souza Lima ^h, Caroline Bonamin Solo ⁱ, Emmanuella Graciott Souza ^d,
Andre Magalhaes Fernandes ^j, Angelo Maiolino ^{a,k}, Vania Hungria ^{l,m}

^a Universidade Federal do Rio de Janeiro (UFRJ), Brazil

^b Transplant Unit, Complexo Hospitalar de Niterói (DASA - CHN), Brazil

^c Hospital Universitário Professor Edgar Santos (HUPES), Universidade Federal da Bahia, Brazil

^d Universidade Federal de Minas Gerais, Brazil

^e Universidade Federal do Rio Grande do Sul, Brazil

^f Clínica Viver- CEPHON, Florianópolis, Brazil

^g Universidade Federal de Juiz de Fora, Brazil

^h IHOC/Curitiba, Curitiba, Brazil

ⁱ HC - UFPR, Curitiba, Brazil

^j Clínica CEHON- Juazeiro, Brazil

^k Américas Centro de Oncologia Integrado, Brazil

^l Hematology, Santa Casa Medical School, Brazil

^m São Germano Clinic, Brazil

ARTICLE INFO

Article history:

Received 18 March 2023

Accepted 4 August 2023

Available online 13 September 2023

Keywords:

Multiple myeloma

SARS-Cov 2

ABSTRACT

Introduction: This study evaluated outcomes and risk factors for COVID-19 in 91 Brazilian multiple myeloma (MM) patients between April 2020 and January 2022.

Results: Of the 91 MM patients diagnosed with COVID-19, 64% had comorbidities and 66% required hospitalization due to COVID-19, with 44% needing ventilatory support and 37% intensive care. Age (OR 2.02; 95%CI 1.02 – 7.7) and hypertension OR 4.5; 95%CI 1.3 – 15.5) were independently associated with hospitalization and certain MM therapies (corticosteroids and monoclonal drugs) were associated with ventilatory support (OR 4.3; 95%CI 1.3 – 14 and OR 5.7; 95%CI 1.8 – 18, respectively), while corticosteroids and immunomodulatory drugs were

* Corresponding author at: Department of Internal Medicine, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255 Sala 4A 12, 21941-913 Rio de Janeiro, Brazil.

E-mail address: marciagarnica@hucff.ufjf.br (M. Garnica).

<https://doi.org/10.1016/j.htct.2023.08.002>

2531-1379/© 2023 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

COVID-19
Mortality
Infection

linked to ICU admission (OR 5.1; 95% CI 1.4 – 18 and OR 3.4; 95%CI 1.1 – 10, respectively). The overall mortality rate was 30%, with the highest rate observed in the ICU (73%). Additionally, the ECOG performance status was linked to increased mortality (OR 11.5; 95%CI 1.9 – 69). The MM treatment was delayed in 63% of patients who recovered from COVID-19.

Conclusions: The findings highlight the need for preventing COVID-19 and prioritizing vaccination among MM patients, as they have high rates of severe outcomes in the event of COVID-19. It is also essential to monitor the potential clinical impacts of COVID-19 on MM patients in the long-term. Given the limited resources available in treating MM patients in Brazil during the COVID-19 pandemic, outcomes might be worse in this population.

© 2023 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Multiple myeloma is characterized by severe immunosuppression, leaving patients at high risk of infections and of developing severe and life-threatening complications. Infection risk often relates to disease-related immunoparesis, age, comorbidities and systemic therapy.¹⁻³ The COVID-19 pandemic has impacted oncological care, including delays in diagnosis and treatments, but, additionally, regarding several cases of COVID-19 infections in this high-risk population.⁴ For patients in treatment for multiple myeloma, the same was observed.⁵ The MM patients showed a higher risk for the SARS-CoV-2 infection and a higher excess mortality in 2020 (difference in excess mortality) than non-MM patients.⁶ The outcome can be even worse in Brazil, where the scenario is of restricted resources to treat MM patients and large numbers of COVID-19 cases and related deaths.

In this cooperative study, we aimed to assess risk factors and outcomes of COVID-19 in Brazilian patients with MM and describe the impact of the infection on the MM treatment.

Methods

This was a cooperative retrospective multicenter study performed nationally by the “Grupo Brasileiro de Mieloma” (GBRAM). Patients with multiple myeloma followed at the participating centers and diagnosed with COVID-19 (SARS-CoV 2 polymerase chain reaction (PCR)- positive test) from April 2020 to Jan. 2022 were included in this study. The study included cases managed in and out of the hospital reported by 12 centers in 8 different states, representing 4 of the 5 Brazilian regions.

This research was conducted following the Declaration of Helsinki and was approved by the Ethical Committee of each center under CAAE number 30907420.1.0000.5455.

The medical records of the patients were used to collect the following baseline characteristics: time from diagnosis to COVID-19 infection, age at COVID-19 event, ECOG performance status, comorbidities and myeloma International Staging System (ISS) at MM diagnosis. The current MM therapy and previous stem cell transplant data were also collected.⁴⁴

Regarding COVID infection, we collect data concerning symptoms of infection onset and COVID-19 vaccination status.

Clinical features and risk factors were analyzed with the severity of COVID-19 and the following outcomes: hospital admissions, intensive care unit (ICU) admission, ventilatory support, and death. MM treatment modification due to COVID-19 was also accessed.

Statistical analyses

Categorical and continuous numeric variables were explored using the chi-square or Fisher exact test, Wilcoxon rank-sum test, or Spearman correlation test; the results were expressed as frequencies and medians. Crude and adjusted odds ratios (OR) were estimated with logistic regression analysis for the outcomes. A p-value lower than 5% was considered significant. All analyses were performed with the IBM SPSS statistical package (SPSS Statistics for MAC, Version 27, IBM Corp).

Results

The characteristics of the 91 MM patients were reported in [Table 1](#). There was 50% male with a median age of 62 (33 – 84) years and 30% ISS III at diagnosis. At least one comorbidity was present in 52 (64%) patients: most frequently hypertension and diabetes (52% and 23%). Twenty-eight (35%) patients had more than one comorbidity.

During the COVID episode, 23 (26%) patients had an active or progressing disease, and 37% received at least two prior lines of treatment.

Corticosteroids were the class of MM therapy most frequent used (n=57, 63%), followed by immunomodulatory drugs (n=51, 55%) at the onset of COVID.

COVID-19 infections were classified as at least moderate in (n=60) 66%, and the event management required hospitalization in 60 (66%), ventilatory support in 40 (44%), and ICU admission in 34 (37%). As the cohort started in 2021, most events (74%) occurred in patients not exposed to COVID-19 vaccines.

Patients who required hospitalization were older and had more frequent comorbidities. ([Table 2](#)) Previous stem cell transplants were less frequent in patients who required hospitalization (30 vs. 55%; p=0.025) compared with controls. The frequency of treatment with immunomodulatory and monoclonals was more frequent in patients who required hospitalization (66 vs. 45%, p=0.07; and 37% vs. 13%, p=0.025)

Table 1 – Baseline patients characteristics.

	n = 91
Age, median, years	62 (33 – 84)
Age group, n (%), in 83	
< 65y	46 (55)
65 - 75	27 (33)
> 75	10 (12)
Unknown/not documented	8
Gender, n (%) in 89	
Male	45 (51)
Female	43 (49)
Unknown/not documented	3
ISS stage (ISS), n (%), in 76	
Stage I	30 (39)
Stage II	23 (30)
Stage III	23 (30)
Unknown/not documented	15
ECOG status, n (%), in 76	
0 – 1	67 (88)
2 - 4	9 (12)
Unknown/not documented	15
Comorbidities, n (%) in 81	
None	29 (36)
At least one	52 (64)
More than one	28 (35)
Unknown/not documented	10
Hypertension	42 (52)
Diabetes	19 (23)
Cardiac Disease	12 (15)
Renal Disease	8 (10)
Pulmonary disease	6 (7)
Obesity	4 (5)
MM status at COVID, n (%) in 88	
Remission (CR, VGPR, PR)	65 (74)
Stable disease	18 (20)
Progression	5 (6)
Unknown/not documented	3
Previous SCT, n (%) in 88	
Yes	35 (40)
No	56 (64)
Unknown/not documented	3
Lines of therapy before COVID, n (%) in 88	
1	54 (61)
2	16 (7)
> 3	18 (20)
Unknown/not documented	3
Current Treatment at COVID, n (%)	
Corticosteroids	57 (63)
Immunomodulatory drugs	51 (55)
Proteasome inhibitors	38 (42)
Monoclonals	25 (27)
Alkylating agents	19 (21)
COVID-19 vaccine status, n (%) in 89	
Non-vaccinated in the event	66 (74)
Vaccinated before COVID event	23 (26)
Unknown/not documented	2
COVID-19 clinical features	
Clinical severity, n (%)	
Mild	31 (34)
Moderate-Severe	26 (29)
Critical	34 (37)
Symptoms at diagnosis	
Fever	55 (61)
High respiratory tract	33 (37)
Low respiratory tract	47 (52)
COVID Management	
Hospitalization	60 (66)

Table 1 (continued)

	n = 91
Ventilatory support	40 (44)
Intensive care	34 (37)
Outcomes, n (%) in 86	
Recovered	60 (70)
Death	26 (30)
Ongoing/ Unknown/not documented	5
Note: percentages of valid cases.	

Table 2 – Characteristics of patients who required or not hospitalization for COVID care.

	Hospitalized n = 60	Non-Hospitalized n = 31	p-value
Age group, n (%)			0.008
< 65y	24 (44)	22 (76)	
65 - 75	20 (37)	7 (24)	
> 75	10 (18)	0	
Gender			NS
Male	30 (51)	15 (52)	
Female	29 (49)	14 (48)	
ISS stage (ISS), n (%)			NS
Stage I	18 (37.5)	12 (43)	
Stage II	14 (29)	9 (32)	
Stage III	16 (37)	7 (25)	
ECOG status			NS
0 – 1	40 (83)	27 (96)	
2 - 4	8 (17)	1 (4)	
Comorbidities			0.010
None	15 (26)	14 (58)	
At least one	42 (74)	10 (42)	
More than one	25 (44)	3 (12.5)	0.010
Hypertension	35 (61)	7 (29)	0.014
Diabetes	16 (28)	3 (12)	NS
Cardiac Disease	10 (17.5)	2 (8)	NS
Renal Disease	8 (14)	0	NS
Pulmonary disease	5 (9)	1 (4)	NS
Obesity			NS
MM status at COVID			NS
Remission (CR, VGPR, PR)	41 (72)	24 (77)	
Stable disease	12 (21)	6 (19)	
Progression	4 (7)	1 (3)	
Previous SCT			0.025
Yes	18 (30)	17 (55)	
No	42 (70)	14 (45)	
Lines of therapy before COVID			NS
1	36 (62)	18 (60)	
2	9 (15.5)	7 (23)	
> 3	13 (22)	5 (17)	
Current Treatment at COVID			NS
Corticosteroids	41 (71)	16 (52)	NS
Immunomodulatory drugs	37 (66)	14 (45)	0.07
Proteasome inhibitors	25 (44)	13 (42)	NS
Monoclonals	21 (37)	4 (13)	0.025
Alkylating agents			
COVID-19 vaccine status			NS
Non-vaccinated in the event	42 (72)	24 (77)	
Vaccinated before COVID event	16 (28)	7 (23)	
Symptoms at diagnosis			0.012
Fever	42 (71)	13 (42)	NS
High respiratory tract	23 (39)	10 (32)	NS
Low respiratory tract	37 (63)	10 (32)	0.008

Note: percentages and statistics including only valid cases; NS: not statistically significant.

Table 3 – Characteristics of patients who required or not (Controls) ventilatory support for COVID care.

	Ventilatory support n = 40	Controls n = 51	p-value
Age group, n (%)			0.023
< 65y	20 (56)	26 (55)	
65 - 75	8 (22)	19 (40)	
>75	8 (22)	2 (4)	
Gender			NS
Male	23 (59)	22 (45)	
Female	16 (41)	27 (55)	
ISS stage (ISS), n (%)			NS
Stage I	14 (47)	16 (35)	
Stage II	8 (27)	15 (33)	
Stage III	8 (37)	15 (33)	
ECOG status			NS
0 – 1	26 (81)	41 (93)	
2 - 4	6 (19)	3 (7)	
Comorbidities			NS
None	12 (32)	17 (39)	
At least one	25 (68)	27 (61)	
More than one	16 (43)	12 (27)	0.16
Hypertension	20 (54)	22 (50)	NS
Diabetes	10 (27)	9 (20)	NS
Cardiac Disease	8 (22)	4 (9)	NS
Renal Disease	4 (11)	4 (9)	NS
Pulmonary disease	4 (11)	2 (4)	NS
Obesity	3 (8)	1 (2)	NS
MM status at COVID			NS
Remission (CR, VGPR, PR)	32 (82)	33 (67)	
Stable disease	5 (13)	13 (26.5)	
Progression	2 (5)	3 (6)	
Previous SCT			NS
Yes	12 (30)	23 (45)	
No	28 (70)	28 (55)	
Lines of therapy before COVID			NS
1	23 (60)	31 (62)	
2	6 (16)	10 (20)	
> 3	9 (24)	9 (18)	
Current Treatment at COVID			
Corticosteroids	30 (77)	27 (54)	0.028
Immunomodulatory drugs	27 (73)	24 (48)	0.028
Proteasome inhibitors	19 (50)	19 (38)	NS
Monoclonals	18 (46)	7 (14)	0.002
Alkylating agents			
COVID-19 vaccine status			
Non-vaccinated in the event	27 (69)	39 (78)	NS
Vaccinated before COVID event	12 (31)	11 (22)	
Symptoms at diagnosis			
Fever	28 (72)	27 (53)	0.08
High respiratory tract	19 (49)	14 (37)	0.048
Low respiratory tract	23 (59)	24 (47)	NS

Note: Percentages and statistics including only valid cases; NS: not statistically significant.

Table 4 – Characteristics of patients who required (ICU) or not (Controls) Intensive Care for COVID care.

	ICU n = 34	Controls n = 57	p-value
Age group, n (%)			0.003
< 65y	17 (57)	29 (55)	
65 - 75	5 (17)	22 (41)	
> 75	8 (27)	2 (4)	
Gender			NS
Male	18 (54)	27 (49)	
Female	15 (46)	28 (51)	
ISS stage (ISS), n (%)			NS
Stage I	13 (52)	17 (35)	
Stage II	6 (24)	17 (33)	
Stage III	6 (24)	17 (33)	
ECOG status			NS
0 – 1	23 (82)	44 (92)	
2 - 4	5 (18)	4 (8)	
Comorbidities			NS
None	11 (34)	18 (37)	
At least one	21 (66)	31 (63)	
More than one	14 (44)	14 (29)	NS
Hypertension	17 (53)	25 (51)	NS
Diabetes	8 (25)	11 (22)	NS
Cardiac Disease	6 (26)	6 (12)	NS
Renal Disease	4 (12)	4 (8)	NS
Pulmonary disease	2 (6)	4 (8)	NS
Obesity	3 (9)	1 (2)	NS
MM status at COVID			NS
Remission (CR, VGPR, PR)	27 (82)	38 (69)	
Stable disease	4 (12)	14 (25.5)	
Progression	2 (6)	3 (5.5)	
Previous SCT			NS
Yes	10 (29)	25 (44)	
No	24 (71)	32 (56)	
Lines of therapy before COVID			NS
1	20 (61)	34 (62)	
2	5 (15)	11 (20)	
> 3	8 (24)	10 (18)	
Current Treatment at COVID			
Corticosteroids	26 (82)	29 (52)	0.006
Immunomodulatory drugs	26 (73)	25 (45)	0.008
Proteasome inhibitors	17 (51)	21 (38)	NS
Monoclonals	15 (44)	10 (18)	0.015
Alkylating agents			
COVID-19 vaccine status			
Non-vaccinated in the event	24 (73)	42 (75)	NS
Vaccinated before COVID event	9 (27)	14 (25)	
Symptoms at diagnosis			
Fever	23 (70)	32 (56)	NS
High respiratory tract	17 (51)	16 (28)	0.040
Low respiratory tract	20 (61)	27 (47)	NS

Note: Percentages and statistics including only valid cases; NS: not statistically significant.

respectively. Ventilatory support was more frequent in older patients (> 75 years) ($p=0.02$); receiving corticosteroids ($p=0.03$), immunomodulatory ($p=0.03$), or monoclonal drugs ($p=0.002$). (Table 3) Admission in ICU was associated with age ($p=0.003$), MM treatment including corticosteroids ($p=0.006$), immunomodulatory ($p=0.008$), or monoclonal drugs ($p=0.015$). (Table 4)

By adjusted multivariate analysis, age and hypertension ($p=0.05$ and $p=0.02$), respectively, were independently




Figure 1 – Mortality rates per supportive care requirement.

associated with hospitalization; MM therapy, including corticosteroids and monoclonal drugs ($p=0.02$ and $p<0.01$), was related to ventilatory support; treatment with corticosteroids and immunomodulatory drugs ($p=0.01$ and $p=0.03$) were associated with ICU admission. (Table 6)

The overall mortality was 30%. Mortality rates were 45%, 67%, and 73% in hospitalized, ventilatory support, and ICU patients. (Figure 1) By univariate analysis, age ($p=0.028$), ECOG performance status ($p=0.005$), and MM therapy, including corticosteroids ($p=0.015$), were associated with increased mortality. (Table 5) By multivariate model, only ECOG performance status (OR 11.5; 95% CI 1.9 – 69) remained associated with mortality. (Table 6)

Regarding the 60 patients who recovered from COVID, 38 (63%) had the current MM treatment delayed. Patients who did not require hospitalization had a delay in MM treatment in 55% of cases. Those who recovered after hospitalization, ventilatory support, or ICU support had 68%, 91%, and 100% of treatment delays.

Discussion

In this series, MM patients diagnosed with COVID-19 had a very high frequency of hospitalization, ventilatory support requirements, ICU admission, and deaths. Although not associated with increased mortality, the therapy regimen was associated with severity condition. There was a high frequency of MM treatment delay in COVID-19 recovered patients.

MM is a disease with severely impaired immunity, including B-cell dysfunction leading to hypogammaglobulinemia, T-cell, dendritic cell, and NK cell abnormalities.⁷ Infection complications are frequent at diagnosis and remain clinically significant during all phases of treatment.^{1,2,8}

A significant impact of the COVID-19 pandemic on MM patients had been expected since the first report of cases, as

viral infections constitute most infections in patients with MM, and the respiratory tract is the most common site.⁹

The Spain Cooperative Group provided the outcomes of a large national cohort of MM patients hospitalized with confirmed SARS-CoV-2 infection. Regarding their data, MM patients had mortality rates 50% higher than noncancer patients with COVID-19.¹⁰ In a report from a single center, including patients with COVID-19 managed as in and out-patient, the infection course was most moderate or severe, with 56% requiring hospitalizations, 20% of intensive care, and 18% of deaths.¹¹ The in-patient mortality of both studies was around 30%-35%. Our patients required more often hospitalization and a significantly higher in-patient mortality rate (45%); three in four cases requiring ICU support were deceased in our cohort.

ECOG performance status was our cohort's most critical risk factor for mortality. ECOG performance status is a validated fragility score and an outcome predictor in cancer patients, independent of age and comorbidities index. The other COVID cohorts in MM patients had also addressed age, renal disease, and active/progressive disease as predictors of COVID outcome.^{11,12}

Although none of the prior MM treatments significantly influenced the mortality rate in our cohort, they were associated with the severity of the infection. Corticosteroids and monoclonal antibodies increased rates of ventilatory support, and corticosteroids and immunomodulatory drugs were associated with ICU admission.

The MM treatment plays a role in the risk of overall infection, and patients with at more lines of therapy have an increased risk of infection due to cumulative immunosuppression.^{8,9} Corticosteroids increase the risk of all types of infections through various mechanisms, and the risk of infection is directly proportional to the dose of glucocorticoid use. In our cohort, patients treated with combinations including corticosteroids required more ventilatory support and intensive care.

Table 5 – Characteristics of deceased or recovered patients.

	Deceased n = 26	Recovered n = 60	p-value
Age group, n (%)			0.028
< 65y	11 (52)	32 (56)	
65 - 75	4 (19)	21 (37)	
> 75	6 (27)	4 (7)	
Gender			NS
Male	13 (52)	29 (50)	
Female	12 (48)	29 (50)	
ISS stage (ISS), n (%)			NS
Stage I	8 (42)	21 (40)	
Stage II	6 (32)	16 (30)	
Stage III	5 (26)	16 (30)	
ECOG status			0.005
0 – 1	14 (70)	30 (96)	
2 - 4	6 (30)	2 (4)	
Comorbidities			NS
None	8 (35)	19 (36)	
At least one	15 (65)	34 (64)	
More than one	10 (43)	16 (30)	NS
Hypertension	14 (61)	26 (49)	NS
Diabetes	5 (22)	13 (24)	NS
Cardiac Disease	4 (17)	8 (15)	NS
Renal Disease	2 (9)	5 (9)	NS
Pulmonary disease	2 (9)	4 (7.5)	NS
Obesity	1 (4)	2 (4)	NS
MM status at COVID			NS
Remission (CR, VGPR, PR)	21 (84)	41 (71)	
Stable disease	3 (12)	14 (24)	
Progression	1 (4)	3 (5)	
Previous SCT			NS
Yes	8 (31)	26 (43)	
No	18 (69)	34 (57)	
Lines of therapy before COVID			NS
1	12 (50)	37 (63)	
2	4 (17)	12 (20)	
> 3	8 (33)	10 (17)	
Current Treatment at COVID			
Corticosteroids	21 (84)	32 (54)	0.015
Immunomodulatory drugs	18 (72)	28 (49)	0.09
Proteasome inhibitors	13 (54)	22 (37)	NS
Monoclonals	9 (36)	14 (24)	NS
Alkylating agents			
COVID-19 vaccine status			
Non-vaccinated in the event	20 (80)	45 (76)	NS
Vaccinated before COVID event	5 (20)	14 (24)	
Symptoms at diagnosis			
Fever	16 (64)	36 (60)	NS
High respiratory tract	11 (44)	19 (32)	NS
Low respiratory tract	16 (64)	28 (47)	NS

Note: Percentages and statistics including only valid cases; NS: not statistically significant.

Monoclonal antibodies, in our cases, represented by Daratumumab (anti CD38 monoclonal antibody), are associated with the reactivation of latent viral infections, neutropenia, and pneumonia. Some studies reported high frequencies of

severe COVID-19 in MM patients under anti-CD38 treatments.^{13,14} Its mechanism of action can explain the association with the severity of COVID in our cohort.

At last, immunomodulatory drugs were associated with ICU admission in our cohort. IMiDs downregulate the transcription factor PU.1, which disrupts granulocyte differentiation and induces neutropenia, resulting in an increased risk of severe infection at all stages of treatment.^{8,15} Another critical point is the association between thrombosis and IMiDs. As in COVID patients, thrombosis is a concern, and special attention is required.

There were a limited number of breakthrough infections after COVID-19 vaccination in our study. However, as the cohort started before a massive vaccination program in Brazil, no associations can be made. Vaccination is crucial in this population, but seroconversion is lower in MM patients compared to the general population and patients remain at risk of breakthrough infections even after complete vaccination.¹⁶⁻¹⁸

Our results showed that more than half of patients who did not required hospitalization had delayed MM treatment. The rate increases to 100% if the patients recover after ICU admission. An extended follow-up is necessary to evaluate if it could modify the outcome of these patients who survived.

A recent study evaluated the potential changes of the COVID pandemic in the treatment course of MM patients. Analyzing MM patients from more than 280 cancer centers in the US, they noted that patients with MM diagnosis performed during COVID were less likely to initiate treatment than those diagnosed before the pandemic.⁵ Studies in other cancer patients' subgroups also reported modifications in the patient's care during COVID.¹⁰⁻²³

Our study has several limitations. Due to the unequal access to healthcare in our country, which was intensified by the pandemic, our cases may not be representative of the national reality since only cases reported by GBRAM centers were included. Patients from other centers could have had worse outcomes than those reported. Additionally, none of our patients received antiviral drugs such as remdesivir, Paxlovid, or molnupiravir, despite their approval by the Brazilian regulatory agency (Remdesivir was approved in 2021, and others in 2022). Until now, access to treatment has been challenging, even for immunocompromised patients.

On the other hand, the incorporation of various COVID-19 vaccines with different platforms into the national immunization program in Brazil has led to a massive vaccination, and most patients having heterologous vaccine schedules. This variability makes assessing immune status more challenging.

The COVID-19 pandemic has dramatically impacted health care globally, but its impact on managing hematologic malignancies in low-income nations is an even higher challenge. We found that our patients were at the most significant risk of mortality from COVID-19 compared with MM patients from other reports. The increase in mortality among our patients was associated with performance status, but the treatment regimen was associated with disease severity. Most cases had the MM treatment at least delayed, and it needs special attention as it can result in long-term prognosis. These data are not surprising and emphasize the frailty of MM patients in Brazil. To limit severe events in this myeloma setting, close monitoring, optimal vaccination strategies, and access to

Table 6 – Multivariate analysis of clinical outcomes.

	Hospitalization		Ventilatory Support		ICU		Death	
	Univariate p-value	Multivariate p-value (OR; 95%CI)	Univariate (p-value)	Multivariate p-value (OR; 95%CI)	Univariate (p-value)	Multivariate p-value (OR; 95%CI)	Univariate (p-value)	Multivariate p-value (OR; 95%CI)
Age group, n (%)	0.008	0.045 (2.02; 1.02 – 7.7)	0.023	NS	0.003	NS	0.028	NS
ECOG status	-	-	-	-	-	-	0.005	0.008 (11.5; 1.9 – 69)
Hypertension	0.014	0.016 (4.5; 1.3 – 15.5)	-	-	-	-	-	-
Previous SCT	0.025	NS	-	-	-	-	-	-
Corticosteroids*	-	-	0.028	0.015 (4.3; 1.3 – 14)	0.006	0.011 (5.1; 1.4 – 18)	0.015	NS
Immunomodulatory drugs*	0.07	NS	0.028	NS	0.008	0.031 (3.4; 1.1 – 10)	0.09	NS
Monoclonals *	0.025	NS	0.002	0.003 (5.7; 1.8 – 18)	0.015	-	NS	-

* Myeloma treatment at COVID-19 event; ICU: intensive care unit; OR: odds ratio; 95%CI: 95% confidence interval; NS: not statistically significant.

treatment remains highly required, particularly in elderly patients with co-morbidities.

Authors' contribution

MG, EQC, GR, AM, and VH were responsible for the conception and design of the study, conducting the search, analysis, and interpretation of data, and drafting the article. EQC, GR, VH, RB, RJPM, KRZ, AEN, JSL, CBS, EGS, and AMF were responsible for data acquisition and provided feedback on the manuscript. All authors reviewed and approved the version to be submitted.

Conflicts of interest

None of the authors has any conflicts of interest (direct or indirect) concerning the manuscript's contents.

Funding

None.

Acknowledgments

We thank all clinical researchers from GBRAM for their support in collecting data.

REFERENCES

- Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. *Haematologica*. 2015;100(1):107–13. <https://doi.org/10.3324/haematol.2014.107714>.
- Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. *Clin Infect Dis*. 2009;49(8):1211–25. <https://doi.org/10.1086/605664>. Oct 15PMID: 19769539.
- Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. *Br J Haematol*. 2015;171(1):100–8. <https://doi.org/10.1111/bjh.13532>. OctEpub 2015 Jun 24. PMID: 26105211.
- UK Coronavirus Monitoring Project TeamLee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet*. 2020;395(10241):1919–26. [https://doi.org/10.1016/S0140-6736\(20\)31173-9](https://doi.org/10.1016/S0140-6736(20)31173-9). Jun 20Epub 2020 May 28. Erratum in: *Lancet*. 2020 Aug 22;396(10250):534. PMID: 32473682; PMCID: PMC7255715.
- Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, et al. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. *Leukemia*. 2022;36(8):2136–9. <https://doi.org/10.1038/s41375-022-01633-x>.
- Martinez-Lopez J, Hernandez-Ibarburu G, Alonso R, Sanchez-Pina JM, Zamanillo I, Lopez-Muñoz N, et al. Impact of COVID-19 in patients with multiple myeloma based on a global data

- network. *Blood Cancer J.* 2021;11(12):198.. <https://doi.org/10.1038/s41408-021-00588-z>. Published 2021 Dec 10.
7. Gur I, Giladi A, Isenberg YN, Neuberger A, Stern A. COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response. *Acta Haematol.* 2022;145(3):297–309. <https://doi.org/10.1159/000523872>.
 8. Caro J, Braunstein M, Williams L, Bruno B, Kaminetzky D, Siegel A, et al. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. *Leukemia.* 2022;36(3):613–24. <https://doi.org/10.1038/s41375-021-01506-9>.
 9. Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. *Clin Lymphoma Myeloma Leuk.* 2021;21(7):444–50. <https://doi.org/10.1016/j.clml.2021.02.002>. e3.
 10. Martínez-López J, Mateos MV, Encinas C, Sureda A, JÁ Hernández-Rivas, Lopez de la Guía A, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. *Blood Cancer J.* 2020;10(10):103.. <https://doi.org/10.1038/s41408-020-00372-5>. Published 2020 Oct 19.
 11. Krejci M, Pour L, Adam Z, Sandecka V, Stork M, Sevcikova S, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. *Ann Hematol.* 2021;100(10):2541–6. <https://doi.org/10.1007/s00277-021-04594-w>. OctEpub 2021 Jul 26. PMID: 34309714; PMCID: PMC8310901.
 12. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. *Blood.* 2020;136(26):3033–40. <https://doi.org/10.1182/blood.2020008150>. Dec 24PMID: 33367546; PMCID: PMC7759145.
 13. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, et al. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. *Am J Hematol.* 2023;98(1):49–55. <https://doi.org/10.1002/ajh.26762>. JanEpub 2022 Oct 24. PMID: 36226510; PMCID: PMC9874728.
 14. Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, et al. Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: initial results of a UK-wide real-world study. *Hematology.* 2022;27(1):691–9. <https://doi.org/10.1080/16078454.2022.2082725>. DecPMID: 35666686.
 15. Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. *Blood.* 2010;115(3):605–14. <https://doi.org/10.1182/blood-2009-05-221077>. Jan 21Epub 2009 Nov 25. PMID: 19965623.
 16. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. *Blood Cancer J.* 2021;11(8):138.. <https://doi.org/10.1038/s41408-021-00530-3>. Aug 2PMID: 34341335; PMCID: PMC8327056.
 17. Song Q, Bates B, Shao YR, Hsu FC, Liu F, Madhira V, et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. *J Clin Oncol.* 2022;40(13):1414–27. <https://doi.org/10.1200/JCO.21.02419>.
 18. Ntanasis-Stathopoulos I, Karalis V, Gavriatopoulou M, Malandrakis P, Sklirou AD, Eleutherakis-Papaikovou E, et al. Second booster BNT162b2 restores SARS-CoV-2 humoral response in patients with multiple myeloma, excluding those under anti-BCMA therapy. *Hemasphere.* 2022;6(8):e764.. <https://doi.org/10.1097/HS9.0000000000000764>. Published 2022 Jul 29.
 19. Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). *J Hematol Oncol.* 2021;14(1):168.. Oct 14.
 20. Bhalla S, Bakouny Z, Schmidt AL, Labaki C, Steinharter JA, Tremblay DA, et al. Care disruptions among patients with lung cancer: a COVID-19 and cancer outcomes study. *Lung Cancer.* 2021;160:78–83. 13.
 21. Riera R, Bagattini AM, Pacheco RL, Pachito DV, Roitberg F, Ilbavi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. *JCO Glob Oncol.* 2021;7:311–23. 14.
 22. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. *Lancet Oncol.* 2020;21:1023–34.
 23. Ranganathan P, Sengar M, Chinnaswamy G, Agrawal G, Arumugham R, Bhatt R, et al. Impact of COVID-19 on cancer care in India: a cohort study. *Lancet Oncol.* 2021;22(7):970–6. [https://doi.org/10.1016/S1470-2045\(21\)00240-0](https://doi.org/10.1016/S1470-2045(21)00240-0).